Allied Minds portfolio company OcuTerra Therapeutics has secured $14.6m in funding.
OcuTerra Therapeutics, a US-based ophthalmology drug developer based on research at Harvard University, has completed a $14.6m series B round.
Investors in the round have not been identified.
Founded in 2011 as SciFluor Life Sciences, OcuTerra is working on a treatment, OTT166, for diabetic retinopathy, a condition affecting the back of the eye. It is a subsidiary of commercialisation firm Allied Minds.
The series B capital will support a phase 2 trial of OTT166.
OcuTerra previously…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
